Aleksejs Sazonovs

Aleksejs Sazonovs

Auto-generated profile, based on publicly available information

Aleksejs Sazonovs

Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
CRChristopher Roberts
Christopher Roberts
JPJaime Peters
Jaime Peters
ASAleksejs Sazonvos
Aleksejs Sazonvos
NGNeil Goodman
Neil Goodman
MSMohmmed Tauseef Sharip
Mohmmed Tauseef Sharip
TATariq Ahmad
Tariq Ahmad
Background: The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.Aims: To report the prevalence, penetrance, expressivity, and pathogenicity of NUDT15 variant allele carriage and the diagnostic accuracy and cost‐effectiveness of an inexpensive loop‐mediated isothermal amplification (LAMP) test.Methods: Retrospective case‐matched cohort study of rates of severe myelosuppression in patients with and without loss‐of‐function NUDT15 variant allele(s) treated with a thiopurine.Results: Overall, 1.3% of Europeans and 11.7% of South Asians carried a variant allele. Severe myelosuppression was associated with NUDT15 variant allele carriage (11.3% vs 0.95%; p < 0.001). Carriage of a single *3, *6 or *9 variant allele was associated with a shorter time to severe myelosuppression. Numbers needed to genotype to prevent myelosuppression in Europeans and South Asians were 786 and 23. Variant calling using the LAMP assay was fully concordant with Sanger sequencing (n = 154). It improved the safety of thiopurine dosing and was cost‐effective when used to reduce the frequency and cost of thiopurine blood monitoring for patients without risk variants.Conclusion: We recommend TPMT and NUDT15 genetic testing in patients of Asian and admixed ancestry. In Europeans, reflex NUDT15 testing should be considered in patients with reduced TPMT activity or loss‐of‐function genotype. Thiopurines should be avoided in patients with > 1 NUDT15 variant allele and in patients with both NUDT15 and TPMT variant alleles. In patients with a single NUDT15 variant allele, we recommend thiopurine dose reduction (< 1 mg/kg/day) and intensified blood test monitoring.

30 July 2025 in American Journal of Gastroenterology
Verified
Journal Article
Open access
AEAnthony Ebert
Anthony Ebert
BVBram Verstockt
Bram Verstockt
MBMartin Bøgsted
Martin Bøgsted
LLLone Larsen
Lone Larsen
GPGry Poulsen
Gry Poulsen
TJTine Jess
Tine Jess
INTRODUCTION: Inflammatory bowel disease (IBD) is associated with various extraintestinal manifestations. We aimed to identify comorbidities in IBD and the timing of their development to provide potentially useful insight into the associations with IBD. METHODS: We conducted a population and disease-wide phenomic association study in IBD, using >6 million International Classification of Diseases, Tenth Revision coded healthcare contacts from 10 years before and up-to 17 years after IBD diagnosis to investigate associations with 1,583 comorbidities. To explore diseases with potential etiological significance, we compared association in the prediagnostic and the postdiagnostic periods. We corrected also for multiple-testing. These estimates were validated with publicly available data from Finland. RESULTS: We identified 312 significant associations with 125 appearing before diagnosis. Risk of extraintestinal manifestations was increased up to 10 years before IBD diagnosis, such as psoriasis (OR CD : 2.58 95% confidence interval: [2.00–3.31]; OR UC : 1.54 [1.26–1.88]) and reactive arthropathies (OR CD : 2.07 [1.42–2.96]; OR UC : 1.42 [1.08–1.84]). Risk of cardiometabolic and neuropsychological disorders was increased both prediagnostically and postdiagnostically. Potential treatment sequelae, such as osteoporosis (HR CD : 2.56 [2.30–2.86]; HR UC : 1.92 [1.79–2.07]) were primarily seen postdiagnostically. In only 15.7% (44/281) and 11.4% (35/301) of comorbidities in Crohn's disease and ulcerative colitis, respectively, did we observe heterogeneity between Denmark and Finland. DISCUSSION: Findings demonstrate that IBD is a multisystemic disease, particularly manifesting with metabolic, immune, and neuropsychological disorders, up to 10 years before diagnosis. We find evidence for the generality of these findings with an international comparison. Diseases of etiological interest warrant further investigation.

11 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NCNathan Constantine-Cooke
Nathan Constantine-Cooke
MVMarie Vibeke Vestergaard
Marie Vibeke Vestergaard
NPNikolas Plevris
Nikolas Plevris
KMKarla Monterrubio-Gómez
Karla Monterrubio-Gómez
CBClara Ramos Belinchón
Clara Ramos Belinchón
CLCharlie W. Lees
Charlie W. Lees
Background: Crohn’s disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic and unpredictable, with a marked disconnect between symptoms and intestinal inflammation. Objective: We aimed to describe latent disease heterogeneity in IBD by identifying longitudinal faecal calprotectin (FC) and CRP patterns. Design: In this longitudinal study, patient-level measurements of FC and CRP in two European cohorts were modelled. Latent class mixed models were used to cluster individuals with similar longitudinal profiles. Associations between cluster assignment and baseline characteristics were quantified using multinomial logistic regression. Differences in advanced therapy use across clusters were explored. Finally, we considered the overlap between FC and CRP clusters. Results: We included 1036 patients in the FC discovery analysis (Lothian) with a total of 10545 FC observations (median 9 per subject, IQR 6–13), and 7880 patients in the replication (Denmark). The CRP discovery analysis consisted of 1838 patients with 49364 measurements (median 20 per subject; IQR 10–36), with 10041 patients in the replication cohort. Eight distinct clusters of inflammatory behaviour over time were identified in the FC and CRP analysis. Similar patterns were observed in the replication cohort. The clusters included rapid remitters, delayed remitters, remitting-relapsing disease, and non-remitters The highest use of early advanced therapy was in the group with the lowest overall inflammation. There was broadly poor agreement between FC and CRP cluster assignment. Conclusion: Distinct patterns of inflammatory behaviour over time are evident in patients with IBD. These data pave the way for a deeper understanding of disease heterogeneity in IBD.

18 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AFAlice Fracchia
Alice Fracchia
JRJonas Julius Rudbaek
Jonas Julius Rudbaek
KCKaustubh Chakradeo
Kaustubh Chakradeo
TJTine Jess
Tine Jess
FOFilip Ottosson
Filip Ottosson
ASAleksejs Sazonovs
Aleksejs Sazonovs
Background: Gestational exposures may contribute to the newborn’s lifetime risk of inflammatory bowel disease (IBD). While gestational influences are associated with IBD onset, the causality and confounding of such exposures are difficult to ascertain. The neonatal metabolome provides a metabolic snapshot of gestational influences. Objective: We tested the neonatal metabolome’s ability to predict future IBD, to assess whether gestational exposures are reflected in early molecular precursors of the disease. Methods: We profiled dried blood spots from 520 newborns who later developed IBD and matched controls using high-resolution untargeted mass spectrometry metabolomics (1,350 QC-passing metabolites). Genotyping was available for 1,009 of these individuals. PERMANOVA confirmed assay sensitivity to gestational exposures, gradient boosting was used for prediction. Results: The neonatal metabolome significantly captured maternal smoking, birth weight, and gestational age (p < 0.001), but explained minimal variance in IBD status (R 2 = 0.09%, p = 0.390) and showed no predictive power for IBD (AUC = 0.51, 95% CI 0.50–0.52, p = 0.585). Stratifying by disease subtype and age of onset did not improve performance. In contrast, genetic risk scores were modestly predictive (CD: AUC = 0.64, p < 5.11×10⁻ 14 ; UC: AUC = 0.63, p < 7.65×10⁻¹²), but uncorrelated with neonatal metabolomic profiles (CD: p = 0.650; UC: p = 0.970), suggesting a later-age effect. Conclusions: Using a large, comprehensively profiled cohort, we demonstrate that neonatal metabolomic profiles sensitively capture gestational signatures, but not the overall future IBD risk. Our findings suggest that most IBD risk accumulates later in life, beyond gestational molecular imprints.